Loading clinical trials...

COMPLETEDPHASE4

Optimal Morphine Dosing Schedule for Neonatal Abstinence Syndrome

NCT04298853•Indiana University

Summary

Randomized pilot trial comparing scheduled morphine dosing with a weaning protocol to intermittent morphine dosing on an as-needed basis for newborns with neonatal abstinence syndrome.

Eligibility

Age

0 - 0 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•newborn greater than or equal to 35 weeks gestation
•intrauterine opioid exposure
•signs and symptoms of opioid withdrawal

Exclusion Criteria

•congenital anomalies or suspected genetic condition
•co-morbid conditions that require sedation or analgesia due to clinical condition
•ongoing need for respiratory support

Locations (1)

Indiana University Health Methodist Hospital

Indianapolis, Indiana, United States

Key Dates

Start Date

June 30, 2020

Primary Completion Date

October 1, 2021

Completion Date

October 1, 2021

Last Updated

October 6, 2022

Enrollment

ACTUAL participants

Conditions

Neonatal Abstinence SyndromeNeonatal Opioid WithdrawalNeonatal Opioid Withdrawal Syndrome

Interventions

Morphine PRN

DRUG

Morphine scheduled

DRUG

Effective Caregiving for Neonatal Abstinence Syndrome: Testing an Instructional Mobile Technology Platform for High-Risk Pregnant Women

NCT04783558

Neonatal Abstinence SyndromeOpioid-use Disorder

View study

ACTIVE_NOT_RECRUITINGNA

Neurostimulation to Improve NOWS Outcomes

NCT05129020

Neonatal Opioid Withdrawal SyndromeNeonatal Abstinence Syndrome

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 6, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Optimal Morphine Dosing Schedule for Neonatal Abstinence Syndrome

Inclusion Criteria

Exclusion Criteria

Effective Caregiving for Neonatal Abstinence Syndrome: Testing an Instructional Mobile Technology Platform for High-Risk Pregnant Women

Neurostimulation to Improve NOWS Outcomes

A Trial to Determine Weight Gain Benefits of Caloric Supplementation for NAS Infants

Trial to Shorten Pharmacologic Treatment of Newborns With Neonatal Opioid Withdrawal Syndrome (NOWS)

Night Respite for Postpartum Mothers With SUD

Clinical Trial to Decrease Length of Stay in Infants With Neonatal Abstinence Syndrome With an Exclusive Human Milk Diet